- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04851418
Pre-hOspital Evaluation of Chest Pain Patients With sUspected Non ST-segment eLevation myocARdial Infarction Using the HEART-score With a Troponin Point-of-care Test (POPular HEART)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Co-primary Objectives:
- To evaluate the interobserver agreement of the HEART-score performed by ambulance personnel compared to the HEART-score performed by emergency physicians.
- To evaluate the diagnostic performance of a strategy based on a pre-hospital HEART-score (with POC cTn testing) or combined with an adjuvant single hs-cTn test at the emergency department to rule-in or rule-out acute coronary syndrome (ACS).
- To evaluate the diagnostic performance of (serial) POC cTn testing or combined with hs-cTn testing compared to (serial) hs-cTn testing to rule-in or rule-out MI.
To investigate the feasibility of using the pre-hospital HEART-score and POC cTn in the 0/1 hour algorithm to rule-out ACS.
Secondary Objectives:
- To evaluate the occurrence of major adverse cardiac events (MACE) in all included patients with a follow up time of 30 days from first medical contact.
- To evaluate the patient reported outcome measures (PROMs) in all chest pain patients transported to the hospital at baseline and at 30 days
- To perform a cost-analysis of an early diagnostic strategy using the pre-hospital HEART-score
Study design: A prospective, observational, single multicentre study Study population: Total number of patients needed for analysis: n=650 Inclusion criteria: - All out-of-hospital chest pain patients visited by an ambulance
- Transportation to a hospital with working diagnosis NSTE-ACS
- Age ≥ 18 years Exclusion criteria: - Comatose state, hemodynamic instability or shock
- Electrocardiographic ST-segment elevation in the pre-hospital setting treated as STEMI
- No pre-hospital 12-lead electrocardiogram performed or available
- An obvious non-cardiac cause for the chest pain (trauma, etc.)
- Suspicion of aortic dissection or pulmonary embolism
- Cognitive impairment
- Pregnancy
- Suspicion of COVID-19 by ambulance
Study procedures: The HEART-score and the POC cTn will be calculated in all included patients in the pre-hospital phase. Simultaneously, a venous blood sample will be drawn from the venous access site for later hs-cTn testing. Outcomes of any pre-hospital study measurements (i.e. pre-hospital POC cTn results or calculated pre-hospital HEART-scores) are blinded to the physicians at the ED and will not affect usual care. According to current practice, all patients will be transported to the hospital for further evaluation. At the emergency department (ED) all included patients will undergo regular hs-cTn testing and HEART-score assessment performed by emergency physicians (standard care), and an extra venous blood sample will be drawn for this study. Additional cTn tests (POC and hs-cTn) will be performed in the laboratory.
Main study parameters/endpoints:
- HEART-score agreement (interobserver variability between pre-hospital and in-hospital HEART-score assessment)
- Final diagnosis of NSTE-ACS at discharge
Myocardial infarction at discharge
Secondary study parameters/endpoints:
- Composite endpoint (cardiovascular mortality, myocardial infarction, urgent revascularisation) at 30 days
- Angina frequency and stability, physical limitations, treatment satisfaction, quality-of-life, cardiac anxiety and depression (SAQ, PHQ-4)
Follow-up: Total follow-up duration is 30 days after initial presentation. Other demographic and clinical parameters at baseline will be taken into account.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: All patients will undergo a POC cTn test performed by ambulance personnel. In all patients, two venous blood samples will be drawn in the pre-hospital phase (1x) and at the emergency department (1x). Besides the minimal risks of performing a POC finger prick test, no other risks are involved with study participation. All patients will be asked to fill in questionnaires (i.e. SAQ, PHQ-4) at baseline and at follow-up.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: JM ten Berg, Prof. Dr.
- Phone Number: +31883201232
- Email: j.ten.berg@antoniusziekenhuis.nl
Study Contact Backup
- Name: J x Azzahhafi, MD
- Phone Number: 0883201311
- Email: j.azzahhafi@anoniusziekenhuis.nl
Study Locations
-
-
-
Nieuwegein, Netherlands, 3435CL
- Recruiting
- St Antonius Hospital
-
Contact:
- J Azzahhafi, MD
- Phone Number: +31883201311
- Email: j.azzahhafi@antoniusziekenhuis.nl
-
Utrecht, Netherlands, 3582KE
- Recruiting
- Diakonessenhuis Utrecht
-
Contact:
- HJ Houtgraaf, MD PhD
- Phone Number: +31882507500
- Email: researchcardiologie@diakhuis.nl
-
Sub-Investigator:
- M Bontje, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- All out-of-hospital chest pain patients visited by an ambulance
- Transportation to a hospital with working diagnosis NSTE-ACS
- Age ≥ 18 years
Exclusion Criteria:
- Comatose state, hemodynamic instability or shock
- Electrocardiographic ST-segment elevation in the pre-hospital setting
- No pre-hospital 12-lead electrocardiogram performed or available
- An obvious non-cardiac cause for the chest pain (trauma, etc.)
- Suspicion of aortic dissection or pulmonary embolism
- Cognitive impairment
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Possible NSTE-ACS
All patients with a suspicion of non-ST-elevation acute coronary syndrome (NSTE-ACS) in the pre-hospital phase are eligible for inclusion.
In all included patients, the POC cTn will be performed and the HEART-score will be calculated in the pre-hospital phase.
Simultaneously, a venous blood sample will be drawn from the venous access site for later hs-cTn testing.
Outcomes of both the POC cTn or the pre-hospital HEART-score will be blinded for the physicians at the emergency department (ED) and will not affect current treatment strategy.
All patients with suspected NSTE-ACS will undergo hs-cTn testing and the HEART-score will also be calculated at the ED (T1, standard of care).
Here, an additional venous blood sample will be drawn next to routine blood testing testing (T1).
|
As mentioned in the group description
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Heart score agreement
Time Frame: 1 year
|
HEART-score agreement (interobserver variability between pre-hospital and in-hospital HEART-score assessment): the calculated heart score by the ambulance will be subtracted from the calculated score of the emergency department.
The minimum value could be -10 and the maximum value could be +10.
A positive score means that the ambulance estimates the patient to be sicker or at higher risk.
A negative value means that the ED estimates the patient to be sicker/at higher risk for developing major adverse cardiac events.
|
1 year
|
Number of participants with final diagnosis of NSTE-ACS
Time Frame: 1 year
|
final diagnosis of NSTE-ACS (non-ST elevation myocardial infarction and unstable angina pectoris) at discharge
|
1 year
|
Number of participants with final diagnosis of myocardial infarction at discharge
Time Frame: 1 year
|
Myocardial infarction at discharge
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with a composite endpoint
Time Frame: 30 days
|
4. The composite endpoint exists out of cardiovascular mortality, myocardial infarction, urgent revascularisation at 30 days
|
30 days
|
Patient reported outcome measure: Seattle Angina questionnaire (SAQ)
Time Frame: 30 days
|
In order to gain information regarding how patients experience their disease, 2 questionnaires will be sent.
The first questionnaire; Seattle Angina questionnaire will assess: angina frequency and stability, physical limitations, treatment satisfaction, and quality-of-life.
|
30 days
|
Patient reported outcome measure: Patient Health Questionnaire 4
Time Frame: 30 days
|
In order to gain information regarding how patients experience their disease, 2 questionnaires will be sent.
The second questionnaire will be the Patient Health Questionnaire 4, will discuss topics such as anxiety, depression and general psychological distress.
|
30 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: HJ Houtgraaf, Dr., Diakonessenhuis, Utrecht
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NL71897.100.19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on Possible NSTE-ACS
-
University Hospital of FerraraCompletedMyocardial IschemiaItaly
-
Alternative Urological Catheter Systems Ltd.Withdrawn
-
Russian Academy of Medical SciencesUnknownAcute Coronary SyndromeRussian Federation
-
Liverpool John Moores UniversityCompletedDiabetes Mellitus, Type 2United Kingdom
-
American Cancer Society, Inc.University of Alabama at BirminghamEnrolling by invitation
-
ROX Medical, Inc.Completed
-
Massachusetts General HospitalCompletedDepression | Myocardial Infarction | Acute Coronary Syndrome | Unstable Angina | STEMI | NSTEMI - Non-ST Segment Elevation MIUnited States
-
St. John's Research InstituteNational Heart and Lung InstituteCompletedAcute Coronary SyndromeIndia
-
ROX Medical, Inc.CompletedChronic Obstructive Pulmonary DiseaseUnited States
-
PfizerTerminatedRotator Cuff TearGermany, Netherlands